Takayuki Takahama
Overview
Explore the profile of Takayuki Takahama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, et al.
Thorac Cancer
. 2025 Feb;
16(3):e70007.
PMID: 39947926
Background: Recognizing rare molecular variants of driver mutations poses a challenge in precision oncology, particularly for treatment of non-small cell lung cancer (NSCLC). In this study, we aimed to determine...
2.
Takeda M, Ota M, Iwama E, Sugawara S, Shukuya T, Umemura S, et al.
Clin Lung Cancer
. 2025 Jan;
PMID: 39743377
Background: MET gene exon 14 skipping was identified as a potential driver mutation that occurs in approximately 3%-4% of patients with nonsmall cell lung cancer (NSCLC), typically in the absence...
3.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, et al.
Mol Clin Oncol
. 2024 Dec;
22(2):14.
PMID: 39720462
We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of (rs17809012) as...
4.
Nakayama T, Takahama T, Chiba Y, Shiraishi N, Kawakami H, Yonesaka K, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39694703
Background: Amplification of the programmed cell death-ligand 1 gene () is highly prevalent and associated with a high response rate to immune checkpoint inhibitors (ICIs) in lymphomas, and is also...
5.
Ikeda S, Hasegawa K, Kachi K, Yanagisawa A, Kawakami S, Hamasaki S, et al.
Cancer Med
. 2024 Nov;
13(21):e70375.
PMID: 39494523
Background: Previous reports indicated still low implementation rates of multigene testing for advanced non-small cell lung cancer (NSCLC) in Japan. Methods: This is a retrospective study launched at the initiative...
6.
Paz-Ares L, Juan-Vidal O, Mountzios G, Felip E, Reinmuth N, de Marinis F, et al.
J Clin Oncol
. 2024 Jun;
42(24):2860-2872.
PMID: 38843511
Purpose: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment...
7.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
8.
Hazama D, Nakahama K, Kodama H, Miyazaki A, Azuma K, Kawashima Y, et al.
JTO Clin Res Rep
. 2024 Jan;
5(1):100613.
PMID: 38229769
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with...
9.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2347700.
PMID: 38100106
Importance: Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient. Objective: To investigate the status of biomarker testing and drug...
10.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, et al.
Oncol Lett
. 2023 Aug;
26(2):355.
PMID: 37545623
There have been few studies on predictive biomarkers that may be useful to select the most suitable opioids to optimize therapeutic efficacy in individual patients with cancer pain. We recently...